ACUR News 1.29 Acura Pharmaceuticals (ACUR)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acura Pharmaceuticals (ACUR) 1.29 $ACUR

Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.

Acura Pharmaceuticals re-acquires rights to its AVERSION Technology from Pfizer
M2 - Thu Apr 10, 5:46AM CDT
Pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) disclosed on Thursday the termination of the license of its AVERSION Technology to Pfizer.

Acura Pharmaceuticals Announces Return of Product Rights
Marketwire - Thu Apr 10, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERSION(R) Technology and the return to Acura of the FDA approved Oxecta(R) (oxycodone HCl) product. The letter agreement provides that Acura will make a one-time payment of $2.0 million to Pfizer. The license termination is effective April 9, 2014. The AVERSION(R) Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.

Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:

Faruqi & Faruqi, LLP Launches An Investigation Against Acura Pharmaceuticals, Inc. (ACUR) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Thu Mar 20, 1:56PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Acura Pharmaceuticals, Inc. ("Acura" or the "Company" (NasdaqCM: ACUR) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for the 2014 Restricted Stock Unit Award Plan ("Plan" .

Acura Pharmaceuticals, Inc. (ACUR) in Focus: Stock Moves 7.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:44AM CDT
Acura Pharmaceuticals, Inc. (ACUR) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 1:00PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.

Stock to Watch: Acura Pharmaceuticals Down 9.6% (ACUR)
Comtex SmarTrend(R) - Tue Mar 04, 10:12AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's worst performing low-priced stocks, down 9.6% to $1.78 on 2.2x average daily volume. Thus far today, Acura Pharmaceuticals has traded 736,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's 1.2%) and underperformed the S&P 500 (-9.6% to the S&P's 1.3%) during today's trading.

Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Mon Mar 03, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.

Acura Pharmaceuticals Up 6.2%, Shares Break Through Resistance (ACUR)
Comtex SmarTrend(R) - Thu Feb 27, 11:40AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 6.2% to $2.06 on 3.4x average daily volume. Acura Pharmaceuticals has traded 972,000 shares thus far today, vs. average volume of 285,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.

Acura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Marketwire - Tue Feb 18, 3:05PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3, 2014. The Company will host a conference call to discuss the results on Tuesday, March 4, 2014 at 8:30 a.m. ET.

Stock to Watch: Acura Pharmaceuticals Up 8.6% (ACUR)
Comtex SmarTrend(R) - Tue Feb 18, 10:11AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 8.6% to $2.01 on 5.5x average daily volume. Acura Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 208,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.1%) and outperformed the S&P 500 (8.6% to the S&P's 0.1%) during today's trading.

Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 7:44AM CST
Acura Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise 5% on the day.

Traders Get Bullish on Shares of Acura Pharmaceuticals, Shares Up 5.7% (ACUR)
Comtex SmarTrend(R) - Fri Feb 14, 10:41AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 5.7% to $1.86 on 3.5x average daily volume. Acura Pharmaceuticals has traded 736,000 shares thus far today, vs. average volume of 210,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.4%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.

4 Stocks Under $10 Moving Higher
at The Street - Fri Feb 14, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Acura Confirms $10M Loan Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 6:05PM CST
Acura confirmed a $10 million debt financing from Oxford Finance.

Acura Pharmaceuticals secures USD10m term loan from Oxford Financing
M2 - Tue Dec 31, 6:07AM CST
Specialty pharmaceutical company Acura Pharmaceuticals Inc (Nasdaq:ACUR) announced on Monday that it has entered into a loan and security agreement with Oxford Finance LLC, under which Oxford has agreed to make a term loan to the company of USD10m in principal amount.

Acura Pharmaceuticals Secures $10.0 Million of Debt Financing
Marketwire - Mon Dec 30, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) entered into a Loan and Security Agreement (the "Loan Agreement" with Oxford Finance LLC, pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of $10.0 million. The loan has a fixed interest rate of 8.35% per annum with interest only payment for the first 15 months and repayment of all principal and interest by December 1, 2018. In addition, at maturity or earlier termination, the Company must pay Oxford an additional one-time interest payment of $795,000. As security for its obligations under the Loan Agreement, the Company granted Oxford a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. The Company may use the proceeds of the Loan Agreement for general working capital and to fund its business requirements.

Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain

Acura Pharma and FDA discuss anti-abuse pain pill
AP - Mon Dec 09, 12:22PM CST
WASHINGTON (AP) — Shares of Acura Pharmaceuticals Inc. rose Monday after the company said it met with federal regulators to discuss a new version of the painkiller hydrocodone that uses the company's abuse-resistant technology.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 94

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Choice Hotels International Advances with 500th Extended Stay Launch

Updated Category News Views 52

Major Growth for Choice Hotels International Choice Hotels International, Inc. (NYSE: CHH) is celebrating a significant milestone as it recently unveiled its 500th extended stay property. This landmark event marks a new chapter in its expansion journey, particularly with the launch of an Everhome Suites. This accomplishment highlights the steady growth and strategic...

Continue Reading
TWC Enterprises Limited to Optimize Shareholder Value Through Buyback

Updated Category News Views 163

TWC Enterprises Limited Launches New Share Buyback Initiative TWC Enterprises Limited (“TWC”) has made a significant announcement regarding its strategy for enhancing shareholder value. The Toronto Stock Exchange (TSX) has accepted TWC’s notice to initiate a normal course issuer bid, which allows the company to buy back shares through the TSX and other Canadian...

Continue Reading
Fluoropolymer Market Growth and Innovations Forecasted

Updated Category News Views 212

Fluoropolymer Market Overview The global fluoropolymer market is experiencing significant growth, anticipated to reach a remarkable valuation of USD 7.3 billion by the year 2034. This growth trajectory represents a compound annual growth rate (CAGR) of 5.2% from the previous valuation of USD 3.9 billion in 2023. The rising demand for fluoropolymers is largely attributed...

Continue Reading
Duluth Trading Company Enhances Customer Engagement with Listrak

Updated Category News Views 85

Duluth Trading Company's Innovations in Customer Communication Listrak's advanced technology will enhance cross-platform personalization for the esteemed lifestyle brand. Duluth Trading Company, a recognized name in the realm of men's and women's workwear, casual attire, and outdoor apparel, has taken a significant step towards enhancing its customer communication by...

Continue Reading
Genuine Parts Company Announces Exciting Quarterly Dividend

Updated Category News Views 105

Genuine Parts Company Announces Quarterly Dividend Genuine Parts Company (NYSE: GPC), a renowned global leader in the supply of automotive and industrial replacement parts, has made an exciting announcement regarding a quarterly dividend. This commitment to delivering value to their shareholders reflects the company's robust performance and ongoing growth. Dividend...

Continue Reading